Allinaire Therapeutics is a biopharmaceutical company based in Beachwood, OH, specializing in the development of innovative therapeutics for cardiopulmonary diseases. Founded in 2016 by BioMotiv and managed by Advent Life Sciences, the company focuses on the advancement of humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies as potential disease-modifying treatments for conditions such as pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.
Under the scientific guidance of founders Matthias Clauss, PhD, and Irina Petrache, MD, along with their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and its network of preclinical and clinical scientists have demonstrated the crucial role of EMAP II in various cardiopulmonary diseases, impacting apoptosis, cell injury, endothelial cell function, and inflammation.
Generated from the website